BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20664960)

  • 1. Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Beppu T; Sugimoto K; Shiraki K; Tameda M; Kusagawa S; Nojiri K; Tanaka J; Yamamoto N; Takei Y; Takaki H; Uraki J; Nakatsuka A; Yamakado K; Takeda K
    Int J Mol Med; 2010 Sep; 26(3):425-33. PubMed ID: 20664960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
    Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
    Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma.
    Ogawa C; Kudo M; Minami Y; Chung H; Kawasaki T
    Hepatogastroenterology; 2008; 55(85):1454-7. PubMed ID: 18795710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.
    Zytoon AA; Ishii H; Murakami K; El-Kholy MR; Furuse J; El-Dorry A; El-Malah A
    Jpn J Clin Oncol; 2007 Sep; 37(9):658-72. PubMed ID: 17766723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma.
    Imamura J; Tateishi R; Shiina S; Goto E; Sato T; Ohki T; Masuzaki R; Goto T; Yoshida H; Kanai F; Hamamura K; Obi S; Yoshida H; Omata M
    Am J Gastroenterol; 2008 Dec; 103(12):3057-62. PubMed ID: 19086957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection.
    Zhang XF; Lai EC; Kang XY; Qian HH; Zhou YM; Shi LH; Shen F; Yang YF; Zhang Y; Lau WY; Wu MC; Yin ZF
    Ann Surg Oncol; 2011 Aug; 18(8):2218-23. PubMed ID: 21336512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
    Kobayashi M; Ikeda K; Kawamura Y; Yatsuji H; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Kumada H
    Cancer; 2009 Feb; 115(3):571-80. PubMed ID: 19117347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Minami Y; Ueshima K; Haji S
    Oncology; 2007; 72 Suppl 1():98-103. PubMed ID: 18087189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.
    Harrison LE; Koneru B; Baramipour P; Fisher A; Barone A; Wilson D; Dela Torre A; Cho KC; Contractor D; Korogodsky M
    J Am Coll Surg; 2003 Nov; 197(5):759-64. PubMed ID: 14585410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma.
    Hayashi K; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Miyata A; Shimizu H; Satomura S
    Am J Gastroenterol; 1999 Oct; 94(10):3028-33. PubMed ID: 10520864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
    Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
    Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma.
    Yoshida S; Kurokohchi K; Arima K; Masaki T; Hosomi N; Funaki T; Murota M; Kita Y; Watanabe S; Kuriyama S
    Int J Oncol; 2002 Feb; 20(2):305-9. PubMed ID: 11788893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
    Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.